Chi K, Yamada Y, Hanada S, Tamura K, Nakamura S, Inagaki H, Ohshima K, Kiyoi H, Ishida T, Matsushima K, Akinaga S, Ogura M, Tomonaga M, Ueda R: Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed sufferers with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J Clin Oncol 2010, 28:1591598. 92. Ishida T, Joh T, Uike N, Yamamoto K, Utsunomiya A, Yoshida S, Saburi Y, Miyamoto T, Takemoto S, Suzushima H, Tsukasaki K, Nosaka K, Fujiwara H, Ishitsuka K, Inagaki H, Ogura M, Akinaga S, Tomonaga M, Tobinai K, Ueda R: Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol 2012, 30:83742. 93. Kim Y, Pinter-Brown L, Foss F, Sokol L, Jorgensen J, Spitalny G, Duvic M: CO26. Final results of a phase 1/2 study for KW-0761, a monoclonal antibody directed against CC chemokine receptor variety four (CCR4), in CTCL patients. Melanoma Res 2011, 21:e15 16. 94. Ogura M, Ishida T, Hatake K, Taniwaki M, Ando K, Tobinai K, Fujimoto K, Yamamoto K, Miyamoto T, Uike N, Tanimoto M, Tsukasaki K, Ishizawa K, Suzumiya J, Inagaki H, Tamura K, Akinaga S, Tomonaga M, Ueda R: Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in sufferers with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. J Clin Oncol 2014, 32:1157163. 95. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M: Distinct recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts lowered survival. Nat Med 2004, ten:94249. 96. Strauss L, Bergmann C, Szczepanski M, Gooding W, Johnson JT, Whiteside TL: A one of a kind subset of CD4+ CD25highFoxp3+ T cells secreting interleukin-10 and transforming development factor-1 mediates suppression within the tumor microenvironment. Clin Cancer Res 2007, 13:4345354. 97. Mizukami Y, Kono K, Kawaguchi Y, Akaike H, Kamimura K, Sugai H, Fujii H: CCL17 and CCL22 chemokines inside tumor microenvironment are connected to accumulation of Foxp3+ regulatory T cells in gastric cancer. Int J Cancer 2008, 122:2286293. 98. Gobert M, Treilleux I, Bendriss-Vermare N, Bachelot T, Goddard-Leon S, Arfi V, Biota C, Doffin AC, Durand I, Olive D: Regulatory T cells recruited by way of CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and result in an adverse clinical outcome.Bapineuzumab Cancer Res 2009, 69:2000009.Celecoxib 99.PMID:33679749 Keir ME, Butte MJ, Freeman GJ, Sharpe AH: PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008, 26:67704. 100. Agata Y, Kawasaki A, Nishimura H, Ishida Y, Tsubata T, Yagita H, Honjo T: Expression from the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol 1996, eight:76572. 101. Yokosuka T, Takamatsu M, Kobayashi-Imanishi W, Hashimoto-Tane A, Azuma M, Saito T: Programmed cell death 1 forms unfavorable costimulatory microclusters that straight inhibit T cell receptor signaling by recruiting phosphatase SHP2. J Exp Med 2012, 209:1201217. 102. Sheppard KA, Fitz LJ, Lee JM, Benander C, George JA, Wooters J, Qiu Y, Jussif JM, Carter LL, Wood CR, Chaudhary D: PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta. FEBS Lett 2004, 574:371. 103. Tsushima F, Yao S, Shin T, Flies A, Flies S, Xu H, Tamada K, Pardoll DM, Chen L: Interaction between B7-H1 and PD-1 determines initiation and re.